Target intelligence / Profile preview

Aprotinin (BPTI)

Target: BPTI
Molecular classification: Serine Protease Inhibitor, Polypeptide, Protein

Overview

Aprotinin is a serine protease inhibitor, primarily used to reduce bleeding during complex surgeries. It inhibits several serine proteases, including trypsin, chymotrypsin, plasmin, and kallikrein, thereby slowing fibrinolysis and reducing blood loss. It also exhibits anti-inflammatory effects.

Other names: Bovine Pancreatic Trypsin InhibitorTrasylol (brand name, now withdrawn)

Mechanism of action

Competitive inhibition of serine proteases (trypsin, chymotrypsin, plasmin, kallikrein)

Biological functions

Inhibition of fibrinolysisInhibition of coagulationAnti-inflammatory activity

Disease associations

Bleeding disordersInflammation

Safety considerations

Anaphylactic reactionsRenal dysfunctionIncreased risk of myocardial infarction (controversial)

Interacting drugs

Heparin

2 more in the full profile.

Beyond the preview

Go deeper on Aprotinin (BPTI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aprotinin (BPTI).

Explore the full profile